Akari Therapeutics Plc

Contributing Author

Recent Articles by Akari Therapeutics Plc

Aug-14	Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech AKTX GlobeNewswire
Jul-29	Akari Therapeutics Releases Virtual Investor "What This Means" Segment AKTX GlobeNewswire
Jul-23	Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers AKTX GlobeNewswire
Jul-22	Akari Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference AKTX GlobeNewswire
Jun-25	Akari Therapeutics Releases Virtual Investor "What This Means" Segment Highlighting its Recently Granted India Patent AKTX GlobeNewswire
Jun-18	Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India AKTX GlobeNewswire
May-29	Akari Therapeutics Releases "Meet the Team" Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development - Oncology AKTX GlobeNewswire
May-22	Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar AKTX GlobeNewswire
May-15	Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update AKTX GlobeNewswire
May-01	Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology AKTX GlobeNewswire